Crossmark

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party

Crossref DOI link: https://doi.org/10.1038/s41409-022-01646-1

Published Online: 2022-05-14

Published Print: 2022-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Duque-Afonso, Jesus https://orcid.org/0000-0002-8287-5673
Finke, Jürgen

Labopin, Myriam https://orcid.org/0000-0003-4514-4748
Craddock, Charles https://orcid.org/0000-0001-5041-6678
Protheroe, Rachel

Kottaridis, Panagiotis

Tholouli, Eleni

Byrne, Jenny L.

Orchard, Kim

Salmenniemi, Urpu

Hilgendorf, Inken https://orcid.org/0000-0003-2038-9730
Hunter, Hannah

Nicholson, Emma

Bloor, Adrian https://orcid.org/0000-0003-4550-220X
Snowden, John A. https://orcid.org/0000-0001-6819-3476
Verbeek, Mareike

Clark, Andrew

Savani, Bipin N.

Spyridonidis, Alexandros https://orcid.org/0000-0003-3097-2532
Nagler, Arnon https://orcid.org/0000-0002-0763-1265
Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
License Information

Text and Data Mining valid from 2022-05-14

Version of Record valid from 2022-05-14
More Information

Article History

Received: 17 December 2021

Revised: 4 March 2022

Accepted: 15 March 2022

First Online: 14 May 2022

Competing interests

: The authors declare no competing interests with the publication of this article. JD-A has received speaker’s honoraria from Roche, Amgen, AstraZeneca, Riemser, and Sobi and travel support from Gilead and Sobi. JF has received research support and speaker’s honoraria from Medac, Neovii, and Riemser. JAS declares advisory board for Medac, and speaker fees for Mallinckrodt, Gilead and Jazz.

Document is current

Any future updates will be listed below